Astria Therapeutics (ATXS) Price & Analysis

Compare

1,166 Followers

ATXS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.56 - $12.52

Previous CloseN/A

Volume35.54K

Average Volume (3M)440.15K

Market Cap

$468.97M

Enterprise Value$151.82M

Total Cash (Recent Filing)$259.18M

Total Debt (Recent Filing)$4.77M

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Nov 12, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding56,434,895

10 Day Avg. Volume470,314

30 Day Avg. Volume440,148

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.32

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.16

Forecast

1Y Price Target

$26.25

Price Target Upside209.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Acquisition StrategyBioCryst Pharmaceuticals announced that it is acquiring Astria in a cash/stock deal that represents an implied ATXS per share value of $13.00.

Therapeutic PotentialNavenibart offers superior efficacy with less frequent injection, supporting at least $1B peak revenue potential and the possibility of capturing at least 50% market share.

Bears Say

Product PortfolioSTAR-0310 has shown ~5-fold lower activated T cell depletion and ~46-fold lower regulatory T cell depletion through antibody-dependent cell-mediated cytotoxicity compared to rocatinlimab.

Strategic FitBioCryst intends to seek strategic alternatives for STAR-0310 due to it not fitting within their rare disease strategy.

Astria Therapeutics News

BioCryst reinstated with a Buy at TD Cowen

TD Cowen reinstated coverage of BioCryst (BCRX) with a Buy rating and $30 price target. The firm is...

9h ago

ATXS

BCRX

Astria Therapeutics downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Astria Therapeutics (ATXS) to Perform from Outperform without a price target after the company reached an...

10h ago

ATXS

BioCryst weakness presents ‘compelling’ buying opportunity, says RBC

RBC Capital raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps an Outperform...

11h ago

ATXS

BCRX

BioCryst price target raised to $15 from $14 at Jefferies

Jefferies analyst Maury Raycroft raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps...

12h ago

ATXS

BCRX

Astria Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies downgraded Astria Therapeutics (ATXS) to Hold from Buy with a price target of $13, down from $30,...

14h ago

ATXS

BCRX

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors will find the latest earnings reports, trade war updates, and business deals moving the stock market on...

14h ago

AMD

Midday Fly By: Big banks report beats, GM takes $1.6B EV charge

The major averages were mixed at midday as the U.S. government shutdown approaches its third week, with traders...

15h ago

Morning Movers: Albertsons gains, Goldman falls after quarterly results

Stock futures are slipping with traders wary that the momentum seen in the prior session could falter in...

18h ago

Video: Banks, dealmakers highlight early movers

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

18h ago

PCH

BioCryst to acquire Astria Therapeutics for $13.00 per share

BioCryst (BCRX) and Astria Therapeutics (ATXS) announced that the companies have entered into a definitive agreement under which...

20h ago

ATXS

BCRX

BioCryst to acquire Astria Therapeutics for $13.00 per share

07:02 EDT BioCryst (BCRX) to acquire Astria Therapeutics (ATXS) for $13.00 per share Published first on TheFly –...

20h ago

ATXS

BCRX

Strategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE Prophylaxis

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Astria Therapeutics and decreased the price target...

12h ago

ATXS

Hold Rating on BCRX Amid Strategic Acquisition of Astria Therapeutics and Market Challenges

In a report released today, Clara Dong from Jefferies downgraded Astria Therapeutics to a Hold, with a price...

14h ago

ATXS

Astria Therapeutics Announces Merger with BioCryst

The latest announcement is out from Astria Therapeutics ( ($ATXS) ). On October 14, 2025, Astria Therapeutics and...

20h ago

ATXS

ATXS FAQ

What was Astria Therapeutics’s price range in the past 12 months?

Astria Therapeutics lowest stock price was $3.56 and its highest was $12.52 in the past 12 months.

What is Astria Therapeutics’s market cap?

Astria Therapeutics’s market cap is $468.97M.

When is Astria Therapeutics’s upcoming earnings report date?

Astria Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.

How were Astria Therapeutics’s earnings last quarter?

Astria Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.588 by $0.018.

Is Astria Therapeutics overvalued?

According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Astria Therapeutics pay dividends?

Astria Therapeutics does not currently pay dividends.

What is Astria Therapeutics’s EPS estimate?

Astria Therapeutics’s EPS estimate is -0.39.

How many shares outstanding does Astria Therapeutics have?

Astria Therapeutics has 56,434,895 shares outstanding.

What happened to Astria Therapeutics’s price movement after its last earnings report?

Astria Therapeutics reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.588. Following the earnings report the stock price went up 3.308%.

Which hedge fund is a major shareholder of Astria Therapeutics?

Currently, no hedge funds are holding shares in ATXS

Astria Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-38.49%

Trailing 12-Months

Asset Growth

-23.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Astria Therapeutics

Astria Therapeutics (ATXS) is a biopharmaceutical company focused on discovering and developing therapies for rare and niche diseases. The company's core mission is to create transformative treatments that improve the lives of patients with unmet medical needs. Astria Therapeutics leverages deep scientific expertise to advance its pipeline of innovative drug candidates targeting specific disease mechanisms.

Astria Therapeutics (ATXS) Earnings & Revenues

Historic Earnings Reports

ATXS Stock 12 Month Forecast

Average Price Target

$26.25

▲(209.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","50":"$50","14.75":"$14.75","26.5":"$26.5","38.25":"$38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.75,26.5,38.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,10.72923076923077,13.918461538461539,17.107692307692307,20.296923076923076,23.486153846153844,26.675384615384615,29.864615384615384,33.05384615384615,36.24307692307692,39.43230769230769,42.62153846153846,45.81076923076923,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,8.97923076923077,10.418461538461539,11.857692307692307,13.296923076923077,14.736153846153847,16.175384615384615,17.614615384615384,19.053846153846155,20.493076923076924,21.932307692307692,23.371538461538464,24.810769230769232,{"y":26.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.54,7.96,8.38,8.8,9.22,9.64,10.06,10.48,10.9,11.32,11.74,12.16,12.58,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >